Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

U.S. business groups warn 'Buy America' order would harm pandemic response

Published 2020-03-26, 08:11 a/m
© Reuters. A worker sells goods behind a makeshift plastic barricade during the outbreak of Coronavirus disease (COVID-19), in the Manhattan borough of New York City

By Andrea Shalal

WASHINGTON (Reuters) - White House plans to expand "Buy America" mandates to the medical equipment and pharmaceutical sectors could worsen shortages of urgently needed medicines and delay discovery of a vaccine for the new coronavirus, over 80 business groups warned.

The U.S. Chamber of Commerce and dozens of other business and trade groups urged U.S. Treasury Secretary Steven Mnuchin, White House economic adviser Larry Kudlow and other top U.S. officials to drop plans for the order, arguing it would also damage U.S. trading relationship for years to come.

"Preventing federal agencies from sourcing medical equipment and pharmaceutical ingredients from abroad ... would only exacerbate the supply shortages racking the United States," said a letter from the groups, which was also addressed to Commerce Secretary Wilbur Ross and U.S. Trade Representative Robert Lighthizer.

White House trade adviser Peter Navarro, a long-time trade hawk who is crafting the order, told Fox News late on Wednesday evening that he expected movement on the issue shortly.

"The president's gonna get that done soon," Navarro told Fox News' "Hannity" program, without giving an exact date.

The push has sparked concern in China and elsewhere, rekindling tensions with Beijing at a moment when global leaders are calling for a coordinated response to the outbreak.

Trump will meet with Chinese President Xi Jinping and other leaders of the world's 20 largest economies in an extraordinary video conference meeting on Thursday to map out a plan to combat the health and economic impacts of the pandemic.

Navarro said the executive order would provide long-term incentives to U.S. companies to produce equipment in the United States through Buy America provisions, deregulation and incentives for 3D printing and other advanced technologies.

In their letter, the groups, including the Pharmaceutical Research and Manufacturers of America, said U.S. industry would "do whatever it takes" to respond to the pandemic, which has infected over 53,000 in the United States and killed 730.

But they said the order could worsen shortages of drugs and medical products and undermine prospects for economic recovery since U.S. companies needed access to international supply chains to produce needed goods.

"The United States cannot shut itself off from the rest of the world," the groups wrote. "Turning our backs on trading partners during a crisis could damage our relationships long after this pandemic ends," they wrote.

© Reuters. A worker sells goods behind a makeshift plastic barricade during the outbreak of Coronavirus disease (COVID-19), in the Manhattan borough of New York City

U.S. trading partners could also retaliate and limit U.S. imports if Washington imposed local content requirements, they said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.